Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.

Autor: Mell LK; Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA. Electronic address: lmell@ucsd.edu., Torres-Saavedra PA; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, MD, USA., Wong SJ; Division of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Kish JA; Division of Hematology Oncology, Department of Medicine, Moffitt Cancer Center, Tampa, FL, USA., Chang SS; Department of Otorhinolaryngology, Henry Ford Health System, Detroit, MI, USA., Jordan RC; NRG Oncology Biospecimen Bank, University of California San Francisco, San Francisco, CA, USA., Liu T; Department of Radiation Oncology, Emory University, Atlanta, GA, USA., Truong MT; Department of Radiation Oncology, Boston Medical Center, Boston, MA, USA., Winquist EW; Department of Oncology, London Regional Cancer Program, London, ON, Canada., Takiar V; Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH, USA., Wise-Draper T; Division of Hematology Oncology, University of Cincinnati, Cincinnati, OH, USA., Robbins JR; Department of Radiation Oncology, University of Arizona College of Medicine, Tucson, AZ, USA., Rodriguez CP; Division of Hematology Oncology, University of Washington, Seattle, WA, USA., Awan MJ; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA., Beadle BM; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA., Henson C; Department of Radiation Oncology, University of Oklahoma, Oklahoma City, OK, USA., Narayan S; Department of Radiation Oncology, Trinity Health Ann Arbor, Ann Arbor, MI, USA., Spencer SA; Department of Radiation Oncology, University of Alabama Birmingham, Birmingham, AL, USA., Powell S; Sanford USD Medical Center, Sioux Falls, SD, USA., Dunlap N; Department of Radiation Oncology, University of Louisville, Louisville, KY, USA., Sacco AG; Division of Hematology Oncology, Department of Medicine, University of California San Diego, La Jolla, CA, USA., Hu KS; Department of Radiation Oncology, New York University Langone Medical Center, New York, NY, USA., Park HS; Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA., Bauman JE; Division of Hematology/Oncology, Department of Medicine, George Washington University and George Washington Cancer Center, Washington, DC, USA., Harris J; NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, USA., Yom SS; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA., Le QT; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Nov 14. Date of Electronic Publication: 2024 Nov 14.

Immune Checkpoint Inhibition for High Grade Meningiomas: A Systematic Review.

Autor: Kaye J; Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. Electronic address: kayejl@ucmail.uc.edu., Na J; Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Atluri S; Idaho College of Osteopathic Medicine, Meridian, Idaho, USA., Ivey N; Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Zack A; Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Chaudhary R; Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Yogendran L; Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Wang K; Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Wise-Draper T; Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Forbes JA; Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Publikováno v: World neurosurgery [World Neurosurg] 2024 Sep; Vol. 189, pp. 203-208. Date of Electronic Publication: 2024 Jun 18.

Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.

Autor: Muquith M; Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Espinoza M; Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX, USA., Elliott A; Caris Life Sciences, Phoenix, AZ, USA., Xiu J; Caris Life Sciences, Phoenix, AZ, USA., Seeber A; Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria., El-Deiry W; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI, USA., Antonarakis ES; Division of Hematology, Oncology and Transplantation, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA., Graff SL; Lifespan Cancer Institute, Legorreta Cancer Center, Brown University, Providence, RI, USA., Hall MJ; Department of Clinical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA., Borghaei H; Department of Hematology-Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA., Hoon DSB; Department of Translational Molecular Medicine, Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA., Liu SV; Division of Hematology and Oncology, Georgetown University, Washington, DC, USA., Ma PC; Penn State Cancer Institute, Hershey, PA, USA., McKay RR; Moores Cancer Center, University of California San Diego Health, La Jolla, CA, USA., Wise-Draper T; Division of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA., Marshall J; Ruesch Center for The Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Sledge GW; Caris Life Sciences, Phoenix, AZ, USA., Spetzler D; Caris Life Sciences, Phoenix, AZ, USA., Zhu H; Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA., Hsiehchen D; Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. gbtwnow@gmail.com.; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. gbtwnow@gmail.com.

Publikováno v: Nature cancer [Nat Cancer] 2024 Jul; Vol. 5 (7), pp. 1121-1129. Date of Electronic Publication: 2024 Mar 25.

Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.

Autor: Hanna GJ; Dana-Farber Cancer Institute, Boston, Massachusetts., Grover P; University of Cincinnati Cancer Center (UCCC), Cincinnati, Ohio., Elliott A; Caris Life Sciences, New York, New York., McGrath J; Phoenix Children's Hospital, Phoenix, Arizona., Xiu J; Caris Life Sciences, New York, New York., Sukari A; Karmanos Cancer Center, Wayne State University, Detroit, Michigan., Johnson JM; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania., Wise-Draper T; University of Cincinnati Cancer Center (UCCC), Cincinnati, Ohio.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 May 15; Vol. 30 (10), pp. 2225-2232.

A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.

Autor: Falchook G; Sarah Cannon Research Institute at HealthONE, Denver, Colorado., Patnaik A; START San Antonio, San Antonio, Texas., Richardson DL; Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; Sarah Cannon Research Institute, Oklahoma City, Oklahoma., Harvey RD; Emory University School of Medicine, Atlanta, Georgia., Sharma MR; START Midwest, Grand Rapids, Michigan., Hafez N; Yale Cancer Center, New Haven, Connecticut., Hamilton E; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee., Piha-Paul SA; Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas., Barve M; Mary Crowley Cancer Research Center, Dallas, Texas., Wise-Draper T; University of Cincinnati Cancer Center, Cincinnati, Ohio., Patel MR; Florida Cancer Specialists, Sarasota, Florida; Sarah Cannon Research Institute, Sarasota, Florida., Dowlati A; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio., Pascuzzo J; Medical Oncology, California Cancer Associates for Research and Excellence, San Diego, California., Tang SC; Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson, Mississippi., Faltermeier C; Pharmacokinetics, IQVIA, Kansas City, Missouri., Malinowska IA; Oncology Clinical Development, GSK, Waltham, Massachusetts., Shtessel L; Oncology Clinical Development, GSK, Waltham, Massachusetts., Striha A; Plus-Project Partnership Ltd, Knutsford, UK., Potocka E; Clinical Pharmacology Modeling and Simulation, GSK, Waltham, Massachusetts. Electronic address: ella.x.potocka@gsk.com.

Publikováno v: Clinical therapeutics [Clin Ther] 2024 Mar; Vol. 46 (3), pp. 228-238. Date of Electronic Publication: 2024 Feb 28.